Peter Kazon is quoted on the Food and Drug Administration’s focus to regulate laboratory-developed tests (LDTs) amid uncertainty over the agency’s final LDT guidance.
In the News
January 20, 2016
Bloomberg BNA | Outlook 2016: Lab Tests, Cybersecurity, Off-Label Use Among Top Device Issues
Media Contact